MDNews - Greater Kansas

October/November 2012

Issue link: http://viewer.e-digitaledition.com/i/86536

Contents of this Issue

Navigation

Page 17 of 19

+++++++++++++++++++++++++++++++++++ +++++++++++++++++++++++++++++++++++ ++++++++++++++ ++++++++++++++ ++++++++++++++ ++++++++++++++ ++++++++++++++ +++++++++++++++++++++++++++++++++++ +++++++++++++++++++++++++++++++++++ THAT'SNEWS Mapping New Roads in the Brain THROUGH A STUDY conducted at the University of Georgia (UGA), researchers have found new ways to map the entire brain. A resulting map will be used to create an updated brain atlas that will complement and go beyond the first one developed by German anatomist Korbinian Brodmann 100 years ago. The new map — developed by Tianming Liu, Ph.D., professor of computer science at the UGA Franklin College of Arts and Sciences, and students Dajiang Zhu and Kaiming Li — pinpointed 358 landmarks throughout the brain by using diffusion tensor imaging. The study results, recently published in Cerebral Cortex, were based on examining hundreds of participants, from which the dense individualized and common connectivity- based coritcal landmarks (DICCCOL) were established. The study was funded by a $1.6 million grant from the National Institutes of Health over the course of five years. Stem-Cell Drug Approved graft-versus-host disease (GVHD), a medical condition affect- ing pediatric patients who typically need painful bone marrow transplants as part of their treatment plans. GVHD quickly leads to death in 80% of patients. In clinical studies of Prochymal, approxi- mately 64% of patients responded to the drug, and survival rates were significantly boosted. These clinical trial results played an important role in Health Canada granting approval. Prochymal is currently used in other countries, including the United States, in limited capacity, based on regulations of the expanded access program. A Worldwide First: Sleep Apnea IN MAY, HEALTH CANADA approved Prochymal (remestemcel-L), mak- ing it the world's first stem-cell drug approved for commercial use. The drug was developed by Osiris Therapeutics, Inc. to treat Raises Risk of Cancer Mortality A NEW STUDY released by the University of Wisconsin School of Medicine and Public Health has found that people who have sleep apnea could be at greater risk of dying from cancer. Led by F. Javier Nieto, M.P.H., M.D., Ph.D., Chair of the Department of Population Health Sciences at the University of Wisconsin School of Medicine and Public Health, the study found that people with sleep-disordered breathing problems have five times higher chances of dying from cancer. The study, backed by the National Institutes of Health's The National Heart, Lung and Blood Institute and the National Institute on Aging, examined the 22-year mortality rate for more than 1,500 participants. The study used data from the ongoing Wisconsin Sleep Cohort study. ADVERTISERS' INDEX MMIC ..................................................................................Back Cover Via Christi Health ............................................ Inside Front Cover Wichita Nephrology Group, P.A. ................ Inside Back Cover 18 | Greater Kansas MD NEWS ■ MDNEWS.COM

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Greater Kansas - October/November 2012